Rimonabant Store
From Buy Online Rimonabant mobilekilnrepair.com
Rimonabant - Rimonamant Online Informations
A patient who is taking rimonabant, a weight loss drug, runs a higher risk of experiencing severe psychiatric events, such as depression and anxiety, according to an article in The Lancet, this week's issue.
The authors explain that as the prevalence of obesity rises unabated, the demand for effective and safe anti-obesity agents that help you lose weight, and keep it off, has grown.
Professor Arne Astrup, Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Denmark, and team carried out a multi-study of four double-blind randomized controlled trials, involving 4,105 patients - they compared patients treated with 20 mg per day with rimonabant versus others who received a placebo.
Rimonabant (also known as SR141716, Acomplia, Bethin, Riobant, Slimona, Rimoslim, and Zimulti)[1] is an anorectic anti-obesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients wih a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries.
Animal studies suggest that cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidemia. The multinational Rimonabant In Obesity (RIO)-Europe study evaluated the effect of rimonabant, a selective CB1 blocker, on weight and cardiovascular risk factors in overweight or obese patients.
In the RIO-Europe study, 1,507 patients with body mass index (BMI) of at least 30 kg/m2 or BMI more than 27 kg/m2 with treated or untreated dyslipidemia, hypertension, or both were randomized to receive double-blind treatment with placebo, 5 mg of rimonabant, or 20 mg of rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The main outcome measure was weight change from baseline after one year of treatment based on intent-to-treat analysis.
At one year, weight loss was greater in patients receiving rimonabant, 5 mg (mean, -3.4 ± 5.7 kg; P = .002 vs placebo) and 20 mg (-6.6 ± 7.2 kg; P < .001 vs placebo) compared with placebo (-1.8 ± 6.4 kg). Weight loss in the rimonabant groups was sustained for around 36 to 40 weeks.
Compared with the placebo group, more patients in the group receiving rimonabant, 20 mg, achieved weight loss of 5% or more (67% of patients; P < .001) and 10% or more (39% of patients; P < .001). This group also had significantly greater improvements than placebo in waist circumference (average reduction, 4 cm), high-density lipoprotein (HDL) cholesterol and triglyceride levels, insulin resistance, and prevalence of the metabolic syndrome.
The effects of rimonabant, 5 mg, were not as marked. Overall, rimonabant was well-tolerated, and adverse effects were mild and transient. In all treatment groups, the most common adverse events leading to study discontinuation were depressed mood disorders. Compared with the other groups, withdrawals for nausea, vomiting, diarrhea, headache, dizziness, and anxiety were more frequent in the 20-mg rimonabant group.
At the American College of Cardiology Scientific Sessions scheduled to take place in early March, among the most anticipated studies to be presented are those involving rimonabant (trade name: Acomplia, from Sanofi-Synthelabo). Rimonabant is the first of a new class of drugs that block the cannabinoid receptor 1 (CB1). The CB1 receptor is thought to play an important role in certain aspects of human behavior and metabolism - specifically, it is thought to play a role in obesity, smoking habits, and lipid and glucose metabolism. The two studies to be presented next month are designed to test the ability of rimonabant to cause weight loss in overweight patients, and smoking cessation in smokers.
The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body's response to tobacco dependence.
Acomplia (rimonabant) has been available in Europe since the middle of 2006, following regulatory approval by the EMEA in June 2006 for its use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaeamia.
Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans, priming and cues. It may also reduce ethanol and opiate seeking behavior.
Sanofi-Aventis, maker of rimonabant, funded the study and provided honoraria to five of the authors.
In an accompanying comment, Uberto Pagotto, MD, and Renato Pasquali, MD, from Sant Orsola-Malpighi General Hospital in Bologna, Italy, note that these findings suggest a weight-independent effect of zimulti on lipid parameters. Whether the mechanism is related to a rise in adiponectin or other mechanisms is still unknown.
